Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102674 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

A Phase 1 study, sponsored by The Medicines Company.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00102674 is a Phase 1 study that has completed, run by The Medicines Company. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102674, a Phase 1 study, has completed, sponsored by The Medicines Company.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The purposes of this study are to: * Evaluate the tolerability of two cangrelor regimens. * Compare the PD of cangrelor regimens with oral clopidogrel.

Interventions

  • DRUG cangrelor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-03
Est. Completion 2005-05
Phase Phase 1

Sponsor

The Medicines Company

35 total trials

What the Registry Record Tells You About NCT00102674

The ClinicalTrials.gov registry entry for NCT00102674 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which cangrelor is the first listed.

NCT00102674 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00102674 about?

NCT00102674 is a clinical study titled "Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor". The purposes of this study are to: * Evaluate the tolerability of two cangrelor regimens. * Compare the PD of cangrelor regimens with oral clopidogrel.

What is the current status of trial NCT00102674?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-03. Estimated completion is 2005-05.

What interventions are being tested in trial NCT00102674?

The interventions under investigation include: cangrelor (DRUG).

Who is sponsoring clinical trial NCT00102674?

This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.